科美诊断(688468) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 was ¥126,051,343.20, a decrease of 7.58% compared to the same period last year[3]. - The net profit attributable to shareholders for Q3 2023 was ¥43,606,643.33, down 10.51% year-on-year[3]. - The net profit excluding non-recurring gains and losses was ¥41,609,611.68, an increase of 6.63% compared to the same period last year[3]. - Total revenue for the first three quarters of 2023 was CNY 345,267,780.87, a decrease of 4.6% compared to CNY 359,915,767.68 in the same period of 2022[17]. - Net profit for Q3 2023 reached CNY 120,238,363.98, an increase of 1.7% compared to CNY 118,250,804.17 in Q3 2022[19]. - Basic and diluted earnings per share for Q3 2023 were both CNY 0.30, compared to CNY 0.29 in Q3 2022[20]. - Operating profit for Q3 2023 was CNY 136,508,794.26, slightly up from CNY 133,965,186.43 in Q3 2022, indicating a growth of 1.1%[18]. - Operating profit increased significantly to CNY 35,396,236.83, up 189.5% from CNY 12,187,317.17 in the previous year[30]. - Net profit for the first three quarters of 2023 reached CNY 39,655,038.70, representing a 107.5% increase from CNY 19,117,201.98 in 2022[30]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,725,319,141.21, representing an increase of 8.43% from the end of the previous year[4]. - As of September 30, 2023, the company's total current assets amounted to ¥1,094,790,539.73, a decrease from ¥1,165,252,004.65 at the end of 2022, representing a decline of approximately 6.05%[13]. - The total assets as of September 30, 2023, were CNY 1,017,896,612.42, a decrease from CNY 1,131,638,710.08 at the end of 2022[27]. - The total current assets decreased to CNY 641,393,396.62 as of September 30, 2023, from CNY 768,574,860.71 at the end of 2022, reflecting a decline of 16.5%[26]. - Total liabilities increased to CNY 363,652,526.37 from CNY 210,591,173.95, reflecting a significant rise in financial obligations[15]. - The total liabilities as of September 30, 2023, were CNY 13,132,734.71, down from CNY 27,382,869.17 at the end of 2022[27]. Cash Flow - The cash flow from operating activities for the year-to-date was ¥124,199,391.92, a decrease of 37.39% compared to the previous year[4]. - The net cash flow from operating activities for Q3 2023 was CNY 124,199,391.92, down 37.3% from CNY 198,363,572.85 in Q3 2022[23]. - In the first three quarters of 2023, the cash inflow from operating activities was CNY 416,659,830.96, a decrease of 3.3% compared to CNY 433,799,291.80 in the same period of 2022[22]. - The company reported a net cash outflow of CNY 64,614,801.88 in Q3 2023, contrasting with a net cash inflow of CNY 57,943,978.99 in Q3 2022[24]. - The total cash inflow from investment activities in the first three quarters of 2023 was CNY 1,830,639,554.31, a decrease of 27.4% compared to CNY 2,520,291,030.32 in the same period of 2022[23]. - The net cash flow from investment activities for Q3 2023 was -CNY 200,962,217.69, worsening from -CNY 61,664,292.63 in Q3 2022[23]. Research and Development - The company's R&D expenditure for Q3 2023 was ¥21,440,724.46, a decrease of 10.25% year-on-year, accounting for 17.01% of operating revenue[4]. - The company reported a decrease in research and development expenses to CNY 47,237,479.89 from CNY 51,337,884.31 in the previous year, a reduction of 7.3%[18]. - Research and development expenses decreased to CNY 27,827,230.08, down 15.9% from CNY 33,055,264.49 in the same period last year[29]. - The company added 8 new domestic medical device certificates during the reporting period, including 6 Class II and 2 Class III registrations[12]. - The company obtained 23 new patents during the reporting period, including 11 domestic invention patents and 6 utility model patents[12]. Future Outlook - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[16]. - The company plans to continue focusing on market expansion and new product development to drive future growth[34].